Create a project of the future — from February 14 to 28, the interuniversity case championship "Young Solutions for BIOMEDTECH" will be held
10.02.2025
Students will have two weeks of online work with a business tracker, participate in the opening of the event and a demo day.
What technological areas are represented?
Available to choose from - "AI for clinical research", "Innovative diagnostics of diseases" and "Innovative prosthetics".
Who can participate?
Students of Skoltech, MIPT, Lomonosov Moscow State University, HSE, Sechenov Moscow State Medical University, Pirogov Russian National Research Medical University, ITMO, Bauman Moscow State Technical University
Among the opportunities for the winners is an internship in partner companies.
You can find out more details and register until February 10 at this link to the link.
For more information, visit the site.Students will have two weeks of online work with a business tracker, participate in the opening of the event and a demo day.
What technological areas are represented?
Available to choose from - "AI for clinical research", "Innovative diagnostics of diseases" and "Innovative prosthetics".
Who can participate?
Students of Skoltech, MIPT, Lomonosov Moscow State University, HSE, Sechenov Moscow State Medical University, Pirogov Russian National Research Medical University, ITMO, Bauman Moscow State Technical University
Among the opportunities for the winners is an internship in partner companies.
You can find out more details and register until February 10 at this link to the link.
For more information, visit the site.
Other news
all news22.05.2025
CDRI Production Company (ChemRar Group) has successfully confirmed its compliance with GMP standards
The Chemical Diversity Research Institute (CDRI LLC , part of the ChemRar Group, Khimki, Moscow Region) has successfully passed the inspection of the Ministry of Industry and Trade of the Russian Federation and received an updated GMP certificate, confirming the current license for the production of medicines for medical use.
Read more31.03.2025
The drug Dipiaron for the treatment of diabetes mellitus from VolgSMU received permission to start clinical trials
A new drug for the treatment of type 2 diabetes mellitus was developed by pharmacologists of the Scientific Center for Innovative Medicines of VolgSMU under the guidance of Corresponding Member of the Russian Academy of Sciences, Professor of the Department of Pharmacology and Pharmacy of the Institute of NMFO of VolgSMU Ivan Tyurenkov. The uniqueness of Dipiaron lies in its ability to preserve beta cells of the pancreas, stimulate the production of incretins and insulin, reduce fasting and postprandial blood glucose levels, reduce food intake and body weight. This will stop the progression of the disease and prevent the development of its later complications.
Read more